Journal Title：Diabetes Therapy

Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.

The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.

《糖尿病治療》是一本國(guó)際性、同行評(píng)審、快速出版（同行評(píng)審 2 周，接受后 3-4 周內(nèi)出版）期刊，致力于發(fā)表高質(zhì)量的臨床（所有階段）、觀察性、真實(shí)世界和健康結(jié)果研究，研究?jī)?nèi)容涉及糖尿病所有領(lǐng)域的治療和干預(yù)（包括設(shè)備）的發(fā)現(xiàn)、開發(fā)和使用。還鼓勵(lì)發(fā)表與診斷、藥物經(jīng)濟(jì)學(xué)、公共衛(wèi)生、流行病學(xué)、生活質(zhì)量以及患者護(hù)理、管理和教育相關(guān)的研究。

該期刊受到廣大醫(yī)療保健專業(yè)人士的關(guān)注，并發(fā)表原創(chuàng)研究、評(píng)論、通訊和信件。該期刊的讀者遍布全球，并收到來(lái)自世界各地的投稿?！短悄虿≈委煛穼⒖紤]所有科學(xué)合理的研究，無(wú)論是正面數(shù)據(jù)、確認(rèn)數(shù)據(jù)還是負(fù)面數(shù)據(jù)。無(wú)論投稿涉及國(guó)際和/或特定國(guó)家的受眾，我們都?xì)g迎投稿，當(dāng)研究人員試圖針對(duì)更具體的患者群體時(shí)，這一點(diǎn)至關(guān)重要。這種包容性的方法使該期刊能夠幫助傳播所有符合科學(xué)和倫理道德的研究。

Diabetes Therapy創(chuàng)刊于2010年，由Springer Healthcare出版商出版，收稿方向涵蓋Medicine - Endocrinology, Diabetes and Metabolism全領(lǐng)域，此刊是中等級(jí)別的SCI期刊，所以過(guò)審相對(duì)來(lái)講不是特別難，但是該刊專業(yè)認(rèn)可度不錯(cuò)，仍然是一本值得選擇的SCI期刊 。平均審稿速度 6 Weeks ，影響因子指數(shù)2.8，該期刊近期沒(méi)有被列入國(guó)際期刊預(yù)警名單，廣大學(xué)者值得一試。